Stonebridge Ventures

Stonebridge Ventures is one of the established venture firms in Seoul, providing substantial expansion capital to deep tech innovators and AI-optimization pioneers as they prepare for public market exits. Nota AI is among the portfolio companies. The healthcare focus concentrates on AI/ML applications and biotech, with a particular interest in companies whose technology has demonstrated clear technical defensibility and commercial momentum.

The thesis is grounded in the observation that South Korea produces world-class deep tech and AI talent and that the bottleneck for many of these companies is access to growth capital that can support the transition from product-market fit to public market readiness. Stonebridge writes meaningful checks at Series A, Series B, and Series C, with the operational and financial sophistication to support companies through to KOSDAQ or international exit. Healthcare investments under this thesis are typically AI-driven companies with strong technical foundations and biotech companies with credible clinical or commercial milestones.

The firm writes checks generally between $5M and $25M, operating across Series A, Series B, and Series C. That stage focus means Stonebridge expects companies to have working products, paying customers, and credible paths to scale by the time a check is written, with diligence calibrated accordingly. Geographically, the firm is anchored in South Korea with selective participation in companies operating internationally from a Korean base, particularly those targeting Japanese, Greater China, or US markets.

The partnership is structured as a professional investment organization with sector specialists and a formal investment committee. Founders should expect a more institutional process than at a typical seed firm, but the trade-off is the credibility and capital depth of one of Korea’s established growth-stage investors. The team has experience taking companies through to public market exits, which is structurally relevant for founders building toward that outcome.

In working with companies, Stonebridge’s most distinctive value is its experience supporting Korean companies through to public listings and its connections into the Korean institutional investor base. The firm helps with growth-stage hiring, investor relations preparation, and the operational maturity required for public market readiness. For healthcare founders, the fit is strongest for AI-driven companies and biotech companies with credible commercial or clinical milestones and the ambition to operate at scale within Korea and across Asia. The fit is weaker for early-stage companies still defining product-market fit or for companies without a credible path to a substantial exit, since the firm’s mandate is calibrated to growth-stage outcomes. Founders considering Stonebridge should plan for an institutional process, bring detailed financial and commercial materials to early conversations, and articulate clearly how the firm’s experience with Korean public market exits aligns with their long-term plans.